Volume 2, Issue 2, December 2018, Page: 47-50
The Resistance of Uropathogenic Bacteria to Fosfomycin
Zohair Ait Ouzdi, Department of Microbiology, Military Hospital Avicenne, Marrakech, Morocco
Lamiae Arsalane, Department of Microbiology, Military Hospital Avicenne, Marrakech, Morocco
Youssef El Kamouni, Department of Microbiology, Military Hospital Avicenne, Marrakech, Morocco
Said Zouhair, Department of Microbiology, Military Hospital Avicenne, Marrakech, Morocco
Received: Nov. 2, 2018;       Accepted: Dec. 18, 2018;       Published: Jan. 7, 2019
DOI: 10.11648/j.plm.20180202.14      View  11      Downloads  4
Abstract
Urinary tract infection is among bacterial infections that provide antibiotic treatment. The overly systematic use of a single class of antibiotic induces a selection pressure leading to bacterial resistance. The purpose of this study is to evaluate the level of resistance and to follow the evolution of the sensitivity of uropathogenic bacteria to fosfomycin to allow a better antibiotherapy of urinary infections. This is a prospective 3-year study of all positive cytobacterioligical urine exam from inpatients or consultants who have arrived at the microbiology laboratory at the Avicenne Military Hospital in Marrakech. Of the 12,116 cytobacterioligical urine exam performed, 1788 met the criteria for urinary tract infection. These urinary infections mainly concerned patients followed externally (1471). The sex ratio between men and women is 1.07. Of the isolated uropathogenic bacteria, E. coli is the predominant strain (51% isolates). Uropathogenic bacteria were sensitive to fosfomycin in more than 90% of cases, and this sensitivity was favorable during the study period. On the other hand, a high frequency of resistance has been recorded for betalactamines, in particular amoxicillin and amoxicillin-clavulanic acid. Fosfomycin has excellent activity on bacteria of urinary tract infections so its single dose prescription would be effective in uncomplicated urinary tract infections.
Keywords
Cytobacterioligical Urine Exam, Uropathogenic Bacteria, Fosfomycin, Resistance
To cite this article
Zohair Ait Ouzdi, Lamiae Arsalane, Youssef El Kamouni, Said Zouhair, The Resistance of Uropathogenic Bacteria to Fosfomycin, Pathology and Laboratory Medicine. Vol. 2, No. 2, 2018, pp. 47-50. doi: 10.11648/j.plm.20180202.14
Copyright
Copyright © 2018 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Reference
[1]
I. Lahlou Amine, M Chegri, H L’Kassmi. Épidémiologie et résistance aux antibiotiques des entérobactéries isolées d’infections urinaires à l’hôpital militaire Moulay-Ismail deMeknès. Antibiotiques 2009; 11: 90—6.
[2]
Gobernado M, Valdés L, Alos JI, Garcia-Rey C, Dal-Re R, Garcia-de-Lomas J, et al. Antimicrobial susceptibility of clinical Escherichia coli isolates from uncomplicatedcystitis in women over a 1-year period in Spain. Rev Esp Quimioter 2007; 20: 68-76.
[3]
J. Sirot, MH Nicolas-Chanoine, H Chardon, JL Avril, C Cattoen, et al. Susceptibility of Enterobacteriaceae to β-lactam agents and fluoroquinolones: a 3-year survey in France. CMI 2002; 8: 207–13.
[4]
P. Honderlick, P. Cahen, J. Gravisse, D. Vignon. Quelle sensibilité aux antibiotiques pour les bactéries responsables d’infections urinaires? Que penser de fosfomycine et nitrofuranes ? Pathologie Biologie 54 (2006) 462–466
[5]
E. Bergogne-Bérézin. Infections urinaires basses: épidémiologie bactérienne et recommandations. Progrès en Urologie 2008; 18 N 1
[6]
Matthew E. Falagas, Evridiki K. Vouloumanou, George Samonis, Konstantinos Z. Vardakasa. Fosfomycin. Clinical Microbiology Reviews. April 2016 Volume 29 Number 2
[7]
Tena D, Gonzalez-Praetorius A, Gonzalez JC, Heredero E, Illescas S, deBaranda CS, et al. Changes in the antimicrobial susceptibility of Escherichia coliisolates from community-diagnosed urinary tract infections during the period2003e2007: a multicenter study in Castilla la Mancha (Spain). Rev Esp Quimioter2010; 23: 36-42.
[8]
Diagnostic et antibiothérapie des infections urinaires bactériennes communautaires de l’adulte. Mise au point. SPILF 2015. Actualisation au 11 décembre 2015 des recommandations initialement mises en ligne en mai 2014
[9]
E. Bergogne-Bérézin. Antibiothérapie des infections urinaires basses: bases cliniques, microbiologiques et pharmacologiques. Antibiotiques 2006; 8: 51-62
[10]
Vrushali Patwardhan, Sarman Singh. Fosfomycin for the treatment of drug-resistant urinary tract infections: potential of an old drug not explored fully. International Urology and Nephrology. September 2017, Volume 49, Issue 9, pp 1637–1643
[11]
F. CARON. Diagnostic bactériologique et antibiothérapie, des infections urinaires. RevPrat 2003; 53: 1760-69.
[12]
F. Bouzenoune et al. Les infections urinaires à Ain M’lila (Algérie). Résistance aux antibiotiques des 239 souches isolées entre 2006 et 2007. Médecine et maladies infectieuses 39 (2009) 142–143.
[13]
M. Moutachakkir, M. Chinbo, N. Elkhoudri, N. Soraa. La résistance aux antibiotiques chez les entérobactéries uropathogènes en milieu pédiatrique au CHU de Marrakech. Journal de pédiatrie et de puériculture (2014).
[14]
J. Boukadida, N. Boukadida, S. Elraii. Profil et sensibilité aux antibiotiques de 2063 bactéries uropathogènes isolées dans le centre de la Tunisie. Bactériologie 2002, p 8_10.
[15]
P. Komp Lindgren, LL. Marcusson, D. Sandvang, N. Frimodt-Moller, D. Hughes. Biological cost of single and multiple norfloxacin resistance mutations in Escherichia coli implicated in urinary tract infections. AAC 2005; 49: 2343–51.
[16]
D. Demouy et al. Sensibilité à la fosfomycine des principales bactéries issues d’infections urinaires observées en pratique de ville chez les femmes de 15 à 65 ans. Med Mal Infect. 1997; 27: 903_6.
[17]
S. Heytens. J Boelens, G Claeys. A. DeSutter, T. Christiaens. Uropathogen distribution and antimicrobial susceptibility in uncomplicated cystitis in Belgium, a high antibiotics prescribing country: 20-year surveillance. European Journal of Clinical Microbiology & Infectious Diseases. January 2017, Volume 36, Issue 1, pp 105–113.
[18]
Naber GK, Schaeffer AJ, Heyns CF et al. Urogenital infections. Ed. 2010. European Association of Urology. – International Consultation on Urological Diseases.
[19]
Falagas ME, Vouloumanou EK, Togias AG et al. Fosfomycin versus other antibiotics for the treatment of cystitis: a meta-analysis of randomized controlled trials. J Antimicrob Chemother 2010; 65: 1862–1877.
Browse journals by subject